Technology developed by Daphne Lab presented at the 12th International Biomedical Congress on Autism and Neurodevelopmental Challenges and the 1st International PANDAS/PANS Symposium. Founder Luigi Di Vaia: “Research represents the essential step in transforming field experience into data that can be observed, compared and shared”

Italy, September 2026 – Daphne Lab’s BioMetaTest® technology took center stage in Buenos Aires during the 12th International Biomedical Congress on Autism and Neurodevelopmental Challenges and the 1st International PANDAS/PANS Symposium, held on September 4 and 5, 2026.

The international event brought together professionals, researchers and specialists from different disciplines to explore topics including neuroimmunology, PANS/PANDAS, the microbiome, the gut-brain axis, nutrition, metabolism, clinical assessment and interdisciplinary approaches to neurodevelopment.

Representing the project in Latin America was FreeFarma, a partner that uses and promotes Daphne Lab’s BioMetaTest® technology in the region, with the participation of CEO Dr. Elizabeth Portugal, Ambassador Dr. Julio Salazar, and Gimena Rojo, FreeFarma’s representative for Argentina and Latin America.

BioMetaTest® and Functional Interpretation

During the congress, Elizabeth Portugal delivered the presentation “Beyond the Symptom: Functional Interpretation through BioMetaTest®”, as part of the session dedicated to biomedical pediatrics and the gut-brain axis.

The presentation focused on the concept of functional interpretation and on the possibility of using BioMetaTest® as a complementary tool within an interdisciplinary approach, integrating the information obtained with the patient’s history, clinical assessment and conventional examinations.

Particular attention was also given to the simplicity of sample collection using a small amount of hair, an aspect that makes the procedure non-invasive and of particular interest in the pediatric setting.

BioMetaTest® tests are not intended for diagnostic or prescriptive purposes and do not replace diagnosis, clinical examinations or any medical treatments that may be required.

“Seeing a technology born from a journey that began more than thirty years ago now reaching international settings where professionals and researchers exchange knowledge on neurodevelopment is a source of great interest and pride for us,” comments Dr. Luigi Di Vaia, founder of Daphne Lab laboratories and creator of the BioMetaTest® methodology.

“From the very beginning, we have worked on the idea that functional information could provide additional elements for observation. Today, the challenge is to ensure that the experience gained in the field is progressively organized, measured and subjected to an increasingly structured research process.”

A New Phase Focused on Research

Research was indeed one of the central themes emerging during BioActitud 2026.

Elizabeth Portugal and Julio Salazar presented a project for an observational, exploratory and multicenter study, planned across ten countries in Latin America and Europe. The project involves the study of children between 3 and 5 years of age with level 3 ASD and the use of Daphne Lab’s BioMetaTest® tests within the research protocol.

The stated objective is to systematize the experience gained through professional practice, collect observable and analyzable data, and investigate what functional information may emerge from the use of these tools within an interdisciplinary approach.

“Research should not start from the result one wishes to obtain, but from the questions,” Di Vaia emphasizes. “We need to observe, measure, compare and verify. If we truly want to understand the possibilities and limitations of a tool, we must also be willing to question our hypotheses and allow the data to guide our conclusions. This is the direction in which we intend to continue working together with our international partners.”

During the event, two PANDAS/PANS cases from Spain and Peru were also presented. They were connected to the work of the interdisciplinary team associated with FreeFarma, with the aim of encouraging professional exchange and generating further research questions.



From Buenos Aires, a Collaboration Looking to the Future

Participation in BioActitud 2026 represents another step in the internationalization of the technology developed by Daphne Lab.

The origins of BioMetaTest® date back to the late 1990s, following research initiated by Luigi Di Vaia in 1994 into the amplification and analysis of biological microsignals. Over the years, this work led to the development of the biospectrophotometry methodology associated with Palladium™ BioMetaTest® technology.

Today, Daphne Lab has a network of more than 1,500 Daphne Points and offers a range of BioMetaTest® tests covering, among other areas, nutrition, mineral analysis, intestinal dysbiosis, fitness and wellness. The company also operates through management systems compliant with ISO 9001 and ISO 14001 standards.

“For us, internationalization does not simply mean bringing BioMetaTest® to new countries,” Di Vaia concludes. “It means building networks among professionals, sharing experiences and, above all, creating the conditions for new scientific questions to emerge from that experience. Buenos Aires is another step in this direction: progressively transforming what we observe into verifiable and shareable knowledge.”

FreeFarma’s participation in BioActitud 2026 therefore represents a journey that brings together technology, professional training, international collaboration and research.

A perspective encapsulated in the words that have accompanied this new phase:
Observe. Measure. Compare. Correlate. Reproduce. Validate. Publish.

Press Contacts
Daphne Lab®
www.daphnelab.com
Massimo Casanova – Commercial Director
export@daphnelab.com
WhatsApp: +39 389 0591308

FreeFarma LATAM
www.freefarma.es
Lic. Elizabeth Portugal
CEO FreeFarma LATAM
Instagram: @freefarmaes | @freefarma.ar
ejecutivafreefarma@gmail.com